In an in vitro degradation assay, the addition of 100 μM of Heparastatin (SF4) completely inhibits the enzyme activity of heparanase at a concentration of 0.15 μg/mL. The addition of Heparastatin, during the transition process, does not affect the phenotypic change of TGF-β-treated cells[2].